The BCR-ABL(35INS) insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP245...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: O'Hare, Thomas, Zabriskie, Matthew S., Eide, Christopher A., Agarwal, Anupriya, Adrian, Lauren T., You, Huihong, Corbin, Amie S., Yang, Fei, Press, Richard D., Rivera, Victor M., Toplin, Julie, Wong, Stephane, Deininger, Michael W., Druker, Brian J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2011
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3217407/
https://ncbi.nlm.nih.gov/pubmed/21908430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-05-349191
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы